Bavencio (Avelumab) Patent Expiration, LOE Window & CMS Spending
Bavencio (Avelumab) by Emd Serono: Biologic BLA (Purple Book Regime), 0 AB generics, $7.9M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Emd Serono |
| FDA Application & Pathway | B761049 (BLA) |
| Exclusivity / Cliff Horizon | Biologic BLA (Purple Book Regime) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $7.9M |
| 2024 Medicare Part D Spend | $2.0M |
| 2024 Medicaid Spend | $5.9M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 21.7% 2-yr change) |